Pharmafile Logo
Pharmafocus logo
Advanced Search

keytruda

Showing 15 posts of 128 posts found.

merckincweb

MSD poised to acquire viral immuno-oncology firm Viralytics for $394m

February 21, 2018
Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

News
merckwindowweb

MSD’s interim Keytruda combo data spooks Roche and BMS

January 16, 2018
Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical

When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …

News
merckwindowweb

Keytruda falls hard at gastric cancer hurdle

December 18, 2017
Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical

There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …

News

MSD withdraws European application of Keytruda combo in lung cancer

October 30, 2017
Sales and Marketing EMA, MSD, keytruda

MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …

News
merckwindowweb

MSD plays catch up with €464m deal for fledgling biotech

September 7, 2017
Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical

MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …

News
merck_and_co

MSD’s Keytruda hits rare snag, floundering in confirmatory trial

July 25, 2017
Manufacturing and Production, Sales and Marketing MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical

Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science …

News
merck_entrance

FDA shutters MSD’s Keytruda combination trials in myeloma

July 6, 2017
Medical Communications, Research and Development MSD, immunotherapy, keytruda, pd-1

Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …

News
microscope-275984_960_720

LifeArc rebrands and sets up £500m research fund

June 15, 2017
Medical Communications, Research and Development, Sales and Marketing LifeArc, MRC Technology, keytruda

The UK medical research charity formerly known as MRC Technology has rebranded to be known as LifeArc. At the same …

News
keytruda3-web

MSD receives first FDA approval based on specific genetic feature

May 24, 2017
Research and Development, Sales and Marketing MSD, Precision Medicine, biomarker, keytruda

In a historic first, MSD (known as Merck in North America) has received approval for its immunotherapy treatment Keytruda in …

News
shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
merck_and_co

MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma

March 15, 2017
Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …

News
shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

Feature
keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023